Shell Offers New AI-Powered Applications Through Open AI Energy Initiative
9.11.2021 17:00:00 EET | Business Wire | Press release
C3 AI (NYSE:AI) and Shell (NYSE:RDS) today announced three new Shell products that will be available through the Open AI Initiative (OAI), an open ecosystem of artificial intelligence (AI)-based solutions for the energy and process industries.
The OAI, launched by C3 AI, Shell, Baker Hughes and Microsoft in February 2021, provides an open framework for energy operators, service & equipment providers, and independent software vendors to offer interoperable solutions, powered by the BHC3 AI Suite and Microsoft Azure. The three new OAI products – Shell Process Optimiser for LNG, Shell Corrosion Advanced Risk Modelling and Analytics, and Shell Autonomous Integrity Recognition – target use cases that will solve key challenges for businesses in the energy industry. By using Shell’s proven domain-specific AI applications built on BHC3’s scalable AI application development platform and SaaS applications, businesses can rapidly move past data discovery and cleaning to application deployment and realization of value in critical business areas.
Details on the new offerings are outlined below:
- Shell Process Optimiser for LNG – The application marries state-of-the-art LNG process engineering and technology with data analytics to enhance asset production by helping asset engineers close the gap between current and optimal production (“gap to potential”) by changing key identified operating conditions as optimization levers. The application integrates sensor information, such as pressure, temperature, and flow rate to calculate the optimum setting using custom-built asset machine learning models. It reveals unknown correlations and sweet spots, and derives the best suitable strategies as optimization know-how. The application, capable of handling operational, economic, and engineering constraints, Shell Process Optimiser for LNG generates actionable insights that can be integrated and brought into the continuous closed loop process control layer for sustained benefits realisation.
- Shell Corrosion Advanced Risk Modelling and Analytics – The application makes use of novel data analytics techniques to predict internal corrosion and erosion to better prioritize and target inspection and maintenance activities. By using a variety of collected site data, and with the help of artificial intelligence, the software provides new insights to predict corrosion and erosion and identify degradation before leaks happen. By using this solution, operators can lower inspection costs and HSSE risk, minimise cost of related leaks, and safely push production to the limit. Additionally, Shell Corrosion Advanced Risk Modelling and Analytics reduces the need for manual, tedious field inspections, resulting in significant time and cost savings.
- Shell Autonomous Integrity Recognition – The application allows inspectors to quickly and easily make use of automated image capture and evaluation to support execution of external integrity inspections. By processing data in the cloud coming from inspections carried out with handheld devices, drones and robots, the solution enables inspectors to objectively evaluate issues, identify items that have been overlooked, reduce the time needed at the desk generating reports, and improve inputs to maintenance planning. Shell Autonomous Integrity Recognition application allows users to identify and classify external corrosion and insulation issues with Machine Vision to reduce leakages. By using this, users can improve the quality, efficiency, and standardization of visual inspections.
These products expand the portfolio of solutions available to OAI subscribers and help accelerate the adoption of enterprise AI in the energy and process industries.
“Previously, there was no framework for Oil and Gas operators to subscribe to proven AI and advanced analytic solutions offered by other operators,” said C3 AI CEO Thomas M. Siebel. “By bringing more solutions built on the BHC3 AI Suite to the OAI, Shell is demonstrating market leadership and establishing the OAI as a one-of-a-kind model of collaboration.”
These applications also broaden the focus areas of the OAI offerings from asset and system reliability to facility and plant optimization and asset integrity, adding to an expanding portfolio of highly differentiated, domain-specific and proven AI applications and modules that are interoperable. These applications can be deployed together to realize business value and create scalable, futureproof reference architectures.
“The products announced today have already been deployed at Shell and have been proven to either create operational efficiencies and savings or generate additional revenue and opportunity,” said Dan Jeavons, Vice President Computational Science and Digital Innovation at Shell. “As more products are added to the growing OAI eco-system, we look forward to working with C3 AI, Baker Hughes, and the other ecosystem partners to build the next-generation platform for the future energy system.”
About C3.ai, Inc.
C3.ai, Inc. (NYSE:AI) is the Enterprise AI application software company that accelerates digital transformation for organizations globally. C3 AI® delivers a family of fully integrated products: C3 AI® Suite, an end-to-end platform for developing, deploying, and operating large-scale AI applications; C3 AI Applications, a portfolio of industry-specific SaaS AI applications; C3 AI CRM, a suite of industry-specific CRM applications designed for AI and machine learning; and C3 AI Ex Machina, a no-code AI solution to apply data science to everyday business problems. The core of the C3 AI offering is an open, model-driven AI architecture that dramatically simplifies data science and application development. Learn more at: www.c3.ai.
About Royal Dutch Shell plc
Royal Dutch Shell plc is incorporated in England and Wales‚ has its headquarters in The Hague and is listed on the London‚ Amsterdam‚ and New York stock exchanges. Shell companies have operations in more than 70 countries and territories with businesses including oil and gas exploration and production; production and marketing of liquefied natural gas and gas to liquids; manufacturing, marketing and shipping of oil products and chemicals and renewable energy projects. For further information, visit www.shell.com. The companies in which Royal Dutch Shell plc directly and indirectly owns investments are separate legal entities. In this document “Shell” is sometimes used for convenience where references are made to Royal Dutch Shell plc and its subsidiaries in general.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005579/en/
Contact information
C3 AI Public Relations
Edelman
Lisa Kennedy
415-914-8336
pr@c3.ai
Investor Relations
ir@c3.ai
Shell Media Relations
Laura van Lingen
+31 (0)70 377 8750
Laura.vanLingen@shell.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Riskified Study Finds Consumers Aren’t Ready to Hand Over Control as AI Transforms Shopping, with Over Half Afraid of Online Fraud27.4.2026 15:00:00 EEST | Press release
Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today released the Q1 2026 edition of its Agentic Commerce Pulse, a quarterly research series tracking agentic commerce risks and consumer engagement. Following Riskified’s inaugural Q4 2025 survey, which first highlighted the rapid emergence of agent-driven commerce, the latest findings reveal a more complex reality: while AI adoption remains strong, consumer trust is not keeping pace. A widening gap is emerging between how shoppers use AI and how much control they are willing to give it. The survey, conducted among consumers across the United States and the United Kingdom, shows that AI is now firmly embedded in product discovery and decision-making. However, compared to Riskified’s agentic commerce pulse survey in Q4 2025, consumer sentiment has shifted, with growing concerns around fraud, security, and accountability slowing the path to fully autonomous, agent-driven transactions. Key findings from th
Nine in 10 Expect Cross-Border M&A Surge, But 71% of Dealmakers Have Already Changed Course on Deals27.4.2026 15:00:00 EEST | Press release
Cross-border M&A is set for a strong resurgence, with nine in 10 senior dealmakers expecting activity to increase over the next 12 to 24 months, according to new research from CSC, the leading provider of business administration and compliance solutions. However, despite this renewed momentum, execution risk is rising, with regulatory scrutiny and operational challenges making it harder to get deals over the line. CSC¹ surveyed 200 director level and above global dealmakers across private equity, corporate, legal, and advisory roles who have worked on cross-border transactions in the past two years. The report, The New Reality of Cross-Border M&A: More Deals, More Friction, explores how firms are navigating an increasingly complex global deal environment. The findings highlight a growing disconnect between ambition and execution. Cross-border transactions are expected to form a significant portion of deal pipelines, with 47% of respondents expecting them to account for between 26% and
Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼ REZZAYO ® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients27.4.2026 14:43:00 EEST | Press release
Mundipharma today announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT). The ReSPECT Phase III trial, one of the largest antifungal, multicentre, randomised, double-blind studies evaluated the efficacy and safety of once weekly rezafungin compared with a SAR for the prophylaxis of IFDs, including infections caused by Candida, Aspergillus, and Pneumocystis, in adults undergoing allogeneic HSCT. Patients undergoing allogeneic HSCT face prolonged periods of immunosuppression and routinely require extended antifungal prophylaxis,1 representing a setting where differentiated dosing, improved side effect profile, and reduced DDI is beneficial, and comparable efficacy is expected. The ReSPECT study met its primary endpoint for US Food and Drug Administration (FDA) and European Medicines
tesa Selects Kinaxis as the Digital Backbone for Global Integrated Business Planning Transformation27.4.2026 14:00:00 EEST | Press release
Kinaxis® (TSX: KXS), a global leader in end‑to‑end supply chain orchestration, today announced that tesa SE, a global manufacturer of adhesive tapes and self-adhesive product solutions, has selected the Kinaxis Maestro™ platform as a core enabler of its global, multi‑year supply chain and integrated business planning (IBP) transformation. Following an extensive evaluation, tesa selected Kinaxis to support its evolution from regionally fragmented planning practices toward a centrally governed, globally orchestrated IBP operatingmodel. Kinaxis will support tesa in improving enterprise-wide transparency, strengthening resilience, and enabling faster, more informed decision making across an increasingly complex and volatile global supply chain network. With 130 years of innovation, tesa is one of the world’s leading manufacturers of adhesive tapes and self-adhesive product solutions. Operating across six global regions and serving both complex industrial and fast-moving consumer markets, t
vVARDIS Announces Investment from Apollo —Achieves Unicorn Status27.4.2026 14:00:00 EEST | Press release
vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260415938477/en/ Photo credit: Jos Schmid, Photographer vVARDIS is redefining the treatment of cavities through its Curodont™ technology, the first and only commercially available non-invasive peptide-containing formulations clinically proven to treat tooth decay. Curodont™ supports en
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
